The group develops their research in the laboratory 209 of the Institute of Biomedicine
of Seville (IBiS). The main objective of the group is the identification of molecular
signaling involved in the antitumoral properties of tyrosine kinase inhibitor (TKI) in
liver cancer cells in different stages of cell differentiation. TKIs are the recommended
treatments for patients with hepatocarcinoma at advanced stage of the disease. In
addition, the identification of epigenetic markers in extracellular vesicles and
circulating tumor cells that might be useful for the diagnosis and prognosis of
hepatocellular carcinoma and the responsiveness to treatments are other relevant
scientific interest of the group.